Orris

New drug which is invented recently

Searching the Web

newly approved drugs 2025 2026 FDA EMA latest

Searching the Web

new drug approvals breakthrough 2026

Here's a roundup of the most notable newly approved drugs in 2025-2026:

New & Noteworthy Drug Approvals (2025-2026)

As of mid-July 2026, the FDA's CDER has approved 24 new molecular entities and biologics in 2026 alone - up from 19 at the same point in 2025. Here are the standout approvals:

Oncology

Revtorpyk (gedatolisib) - Approved July 2026 A multi-targeted PI3K/mTOR kinase inhibitor for metastatic breast cancer (ER+/HER2-negative). Used in combination with fulvestrant. Based on the VIKTORIA-1 trial, it targets multiple parts of a key signaling pathway that cancers exploit to drive resistance. Made by Celcuity - a significant addition to breast cancer therapy.
Padcev (enfortumab vedotin) + Keytruda - EU approval 2026 The first regimen cleared in the EU for muscle-invasive bladder cancer before and after surgery. Trial data showed a 60% reduction in tumor recurrence risk and 50% reduction in death risk.
Trodelvy (sacituzumab govitecan) - EU 2026 Extended approval in triple-negative breast cancer in the EU, used with Keytruda.

Rare & Genetic Diseases

Avlayah (Denali Therapeutics) - Approved March 2026 The first treatment for Hunter syndrome (a rare lysosomal storage disease) that addresses neurological complications - a major milestone as previous therapies could not cross the blood-brain barrier.
Otarmeni (Regeneron gene therapy) - Approved 2026 The first gene therapy targeting an underlying cause of genetic deafness - a landmark in hearing loss treatment.
Kresladi (Rocket Pharmaceuticals) - Approved H1 2026 A gene therapy for leukocyte adhesion deficiency-I (LAD-I), a rare and often fatal immune disease.

Neurology / Psychiatry

Hopledo (levodopa/carbidopa) - EMA recommended June 2026 A new formulation for Parkinson's disease with moderate-to-severe motor fluctuations, for patients not stabilized on oral therapy.
Daybu (trofinetide) - EMA recommended June 2026 For Rett syndrome (a rare neurological disorder) in adults and children aged 5+, treating neurobehavioural symptoms.
Auvelity - FDA approved 2026 for new indication Now approved as the first non-antipsychotic drug for agitation in Alzheimer's disease - considered one of the most important psychopharmacology approvals in recent years.
Cobenfy - Recent approval Described as the first schizophrenia drug targeting cholinergic receptors rather than dopamine - a genuine mechanism shift after decades of dopamine-based antipsychotics.

HIV

Idvynso (doravirine + islatravir) - Approved April 20, 2026 A complete HIV-1 treatment regimen in a single combination product for virologically-suppressed adults looking to switch from their current regimen.

Dermatology

Icotyde (icotrokinra) - Approved March 17, 2026 An IL-17 receptor antagonist for moderate-to-severe plaque psoriasis in patients 12 years and older.

Big Trends in 2026 Approvals

  • Cancer and rare diseases dominate FDA approvals (oncology led overall, rare disease close behind)
  • Gene therapies continue to make headlines, especially for genetic disorders
  • New drug mechanisms (cholinergic for schizophrenia, PI3K/mTOR for breast cancer) are a highlight
  • Median price of new drugs in 2025 was ~$216,000/year - down from $370,000 in 2024, partly because fewer gene therapies launched
  • AstraZeneca and J&J were the biggest winners in H1 2026 with 11 combined total approvals
Sources: FDA Novel Drug Approvals 2026 | BioSpace H1 2026 recap | Fred Hutch on Revtorpyk | EMA June 2026 meeting
Would you like details on any specific drug, disease area, or mechanism of action?
This is a shared conversation. Sign in to Orris to start your own chat.